Principal Findings:

There were 138 nonfatal MIs and 75 coronary deaths. In women younger than 60 years without HRT, the recurrent event rate was 139/10,000 person years and 60 to 75 years 169/10,000. 38.6% of women were never users, 32.4% post users and 32.4% current users of HRT. Of HRT users, 53% used oral conjugated estrogen, 19% in combination with a progestin and 28% other. The age- and other risk-factor–adjusted relative risk for recurrent CVE was 0.65 among current vs. never users of HRT. There was a 25% increase in risk for recurrent CVEs among women using HRT for less than 1 year compared to never; however, longer term HRT was associated with 72% reduction in CVE compared to never users. There was a trend to decreasing risk for CVE with increasing duration (p for trend = 0.002). There was no significant difference in CVE in women who began HRT during the year after the first event compared to previous users. The risk for recurrent major coronary events seems to increase among short-term hormone users with previous coronary disease but to decrease with longer term use.